24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
ADHD
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:25
Israel introduces regulatory sandbox to boost innovation
12:03
Dr. Fareed Zakaria: "People vote based on cultural identification, not purely economic considerations"
11:06
Quantum computing will "be the next big thing after AI," says AT&T VP
11:00
AI and natural disasters: Today’s solution for tomorrow's challenges
More stories
Buzz
Most popular
Daily
Weekly
1
NetApp sells Spot to Flexera for $100 million, four years after $450 million acquisition
2
Lenovo acquires enterprise storage company Infinidat in its first Israeli acquisition
3
Survey finds 50% of high-tech startups in Israel may exhaust funds in six months
4
Warburg Pincus Signs Deal to Acquire Israeli Credit Card Issuer for $680 Million
5
Spot.io founder nets $7 million Seed round to tackle cloud chaos with new startup
More news
ADHD
4 stories about ADHD
“There are so few female founders; this has to be put in the past”
21.08.24
|
Ariela Karmel
Eve Mamane, Co-Founder and CRO of mental health startup Agave Health, spoke to CTech about founding her first venture, the need to normalize female founders, and why the tech industry must eliminate outdated limitations on women in leadership roles
Israeli app launches in the U.S. and Israel, helping parents of ADHD children
15.01.24
|
James Spiro
Pery uses clinical data and LLMs to provide advice and analysis for parents managing children diagnosed with attention deficit hyperactivity disorder
“There is a $5 billion opportunity in the ADHD market”
30.01.23
|
CTech
MindTension has raised a total of $2 million for its tool helping diagnose and treat optimization of ADHD and related mental health comorbidities
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
Please ensure Javascript is enabled for purposes of
website accessibility